What Decheng Capital LLC reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 2010850 · Filed Aug 14, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 26M |
| ±0% |
| $147.4M |
| 20.1% |
AARDAardvark Therapeutics, Inc. | 3.9M | ±0% | $22.6M | 3.1% |
ACRSAclaris Therapeutics, Inc. | 4M | ±0% | $21.4M | 2.9% |
UPBUpstream Bio, Inc. | 2.7M | ±0% | $18.9M | 2.6% |
RCUSArcus Biosciences, Inc. | 464.8K | −2.7% | $14.3M | 2% |
EQEquillium, Inc. | 4.4M | ±0% | $14.2M | 1.9% |
RVMDRevolution Medicines, Inc. | 52.7K | −43.7% | $9.9M | 1.3% |
Lyell Immunopharma, Inc.COM | 692.1K | ±0% | $9.7M | 1.3% |
BYSIBeyondSpring Inc. | 3.8M | ±0% | $6.7M | 0.9% |
ZNTLZentalis Pharmaceuticals, Inc. | 1.3M | ±0% | $6.4M | 0.9% |
NAMSNewAmsterdam Pharma Co N.V. | 176.9K | −45.6% | $6M | 0.8% |
PYXSPyxis Oncology, Inc. | 326.8K | ±0% | $983.7K | 0.1% |
TNGXTango Therapeutics, Inc. | 20K | New | $625.2K | 0.1% |
